422 related articles for article (PubMed ID: 25406647)
21. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
Wolf M; Korja M; Karhu R; Edgren H; Kilpinen S; Ojala K; Mousses S; Kallioniemi A; Haapasalo H
BMC Cancer; 2010 May; 10():181. PubMed ID: 20444257
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease.
Grau E; Martinez F; Orellana C; Canete A; Yañez Y; Oltra S; Noguera R; Hernandez M; Bermúdez JD; Castel V
Mol Carcinog; 2011 Mar; 50(3):153-62. PubMed ID: 21104989
[TBL] [Abstract][Full Text] [Related]
23. FOXP1 is a regulator of quiescence in healthy human CD4
Garaud S; Roufosse F; De Silva P; Gu-Trantien C; Lodewyckx JN; Duvillier H; Dedeurwaerder S; Bizet M; Defrance M; Fuks F; Bex F; Willard-Gallo K
Eur J Immunol; 2017 Jan; 47(1):168-179. PubMed ID: 27861791
[TBL] [Abstract][Full Text] [Related]
24. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas.
Fox SB; Brown P; Han C; Ashe S; Leek RD; Harris AL; Banham AH
Clin Cancer Res; 2004 May; 10(10):3521-7. PubMed ID: 15161711
[TBL] [Abstract][Full Text] [Related]
25. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
26. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
27. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification.
Misawa A; Inoue J; Sugino Y; Hosoi H; Sugimoto T; Hosoda F; Ohki M; Imoto I; Inazawa J
Cancer Res; 2005 Nov; 65(22):10233-42. PubMed ID: 16288011
[TBL] [Abstract][Full Text] [Related]
28. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q.
Fischer M; Bauer T; Oberthür A; Hero B; Theissen J; Ehrich M; Spitz R; Eils R; Westermann F; Brors B; König R; Berthold F
Oncogene; 2010 Feb; 29(6):865-75. PubMed ID: 19901960
[TBL] [Abstract][Full Text] [Related]
29. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
Djos A; Martinsson T; Kogner P; Carén H
Mol Cancer; 2012 Jun; 11():40. PubMed ID: 22695170
[TBL] [Abstract][Full Text] [Related]
30. Non-promoter DNA hypermethylation of Zygote Arrest 1 (ZAR1) in neuroblastomas.
Sugito K; Kawashima H; Yoshizawa S; Uekusa S; Hoshi R; Furuya T; Kaneda H; Hosoda T; Konuma N; Masuko T; Ohashi K; Ikeda T; Koshinaga T; Tomita R; Shinojima Y; Fujiwara K; Watanabe T; Held WA; Nagase H
J Pediatr Surg; 2013 Apr; 48(4):782-8. PubMed ID: 23583134
[TBL] [Abstract][Full Text] [Related]
31. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
32. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
33. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
34. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma.
Lau DT; Hesson LB; Norris MD; Marshall GM; Haber M; Ashton LJ
Clin Cancer Res; 2012 Oct; 18(20):5690-700. PubMed ID: 22929802
[TBL] [Abstract][Full Text] [Related]
36. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
38. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
39. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation.
Parodi F; Carosio R; Ragusa M; Di Pietro C; Maugeri M; Barbagallo D; Sallustio F; Allemanni G; Pistillo MP; Casciano I; Forlani A; Schena FP; Purrello M; Romani M; Banelli B
Biochim Biophys Acta; 2016 Dec; 1859(12):1502-1514. PubMed ID: 27751904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
